Apellis Pharmaceuticals Hits Day Low of $20.66 Amid Price Pressure

Apellis Pharmaceuticals, Inc. has experienced significant volatility today, with the stock hitting an intraday low of USD 20.66, reflecting a notable decline of -31.01%. This sharp drop comes amid a challenging performance landscape for the company, which has seen a year-to-date decrease of -35.04%, contrasting sharply with the S&P 500's gain of 17.15% over the same period.
In the past week, Apellis has declined by -27.54%, and its one-year performance shows a decrease of -25.19%. The company's financial metrics indicate a net profit of -USD 134.38 million, with a debt-equity ratio of 62.89%, suggesting a high level of leverage. Additionally, the return on equity stands at a negative -145.98%, highlighting ongoing financial pressures.

Despite a recent positive performance in December 2024, the company reported negative results in March 2025, contributing to the current market sentiment. As Apellis navigates these challenges, its position within the pharmaceuticals and biotechnology industry remains under scrutiny.